IRLAB Therapeutics AB Class A (DE:6IRA)
FRANKFURT:6IRA
6IRA Stock Chart & Stats
€0.18
-€0.01(-1.25%)
At close: 4:00 PM EST
€0.18
-€0.01(-1.25%)
Day’s Range― - ―
52-Week Range€0.12 - €0.70
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€11.09M
Enterprise Value€69.10M
Total Cash (Recent Filing)€81.86M
Total Debt (Recent Filing)€29.95M
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding84,858,246
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)4.30
Price to Sales (P/S)2.30
P/FCF Ratio-2.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)€10.19M
Bulls Say, Bears Say
Bulls Say
Focused CNS R&D PipelineA dedicated focus on small-molecule CNS drug discovery, with primary emphasis on Parkinson’s and related neurodegenerative diseases, represents a durable strategic position. Specialization can produce deep scientific expertise, clearer trial design, and make the company an attractive partner for licensing or co-development over multiple years.
Improving Leverage; Moderate DebtBalance-sheet leverage has improved with debt roughly matching equity in 2025 versus worse levels in 2024. That improvement reduces near-term refinancing risk and increases financial flexibility to support clinical programs, making the company more resilient to adverse funding conditions over the coming 2–6 months.
Reduced Cash Burn TrendOperating and free cash flow remain negative but have shown improvement in 2024–2025 compared with earlier years. A declining burn rate suggests better cost control or more efficient program spend, extending runway, lowering near-term dilution risk, and supporting continuity of R&D programs over the next several quarters.
Bears Say
Persistent Multi-year LossesThe company moved from profitable 2021 to sustained losses from 2022–2025, producing highly negative margins. Persistent operating losses erode equity, constrain reinvestment capacity, and increase dependency on external funding, which can stress strategic plans and slow clinical progress without new non-dilutive financing.
Negative Cash GenerationConsistent negative operating and free cash flows indicate the business is not self-funding and relies on external capital. Free cash flow roughly matches net losses, showing cash costs mirror accounting losses rather than being mostly non-cash charges, heightening the risk of dilution or disrupted program timelines if funding sources tighten.
Revenue Volatility And DeclineRevenue history shows a large 2021 spike followed by much lower and volatile receipts, with a sharp decline in 2025. This pattern suggests dependence on one-off partnership or milestone payments rather than recurring sales, complicating long-term planning and making funding and program timing more uncertain.
IRLAB Therapeutics AB Class A News
6IRA FAQ
What was IRLAB Therapeutics AB Class A’s price range in the past 12 months?
IRLAB Therapeutics AB Class A lowest stock price was €0.12 and its highest was €0.70 in the past 12 months.
What is IRLAB Therapeutics AB Class A’s market cap?
IRLAB Therapeutics AB Class A’s market cap is €11.09M.
When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?
IRLAB Therapeutics AB Class A’s upcoming earnings report date is May 06, 2026 which is in 31 days.
How were IRLAB Therapeutics AB Class A’s earnings last quarter?
IRLAB Therapeutics AB Class A released its earnings results on Feb 25, 2026. The company reported -€0.026 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.026.
Is IRLAB Therapeutics AB Class A overvalued?
According to Wall Street analysts IRLAB Therapeutics AB Class A’s price is currently Overvalued.
Does IRLAB Therapeutics AB Class A pay dividends?
IRLAB Therapeutics AB Class A does not currently pay dividends.
What is IRLAB Therapeutics AB Class A’s EPS estimate?
IRLAB Therapeutics AB Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IRLAB Therapeutics AB Class A have?
IRLAB Therapeutics AB Class A has 84,858,246 shares outstanding.
What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?
IRLAB Therapeutics AB Class A reported an EPS of -€0.026 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.051%.
Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?
Currently, no hedge funds are holding shares in DE:6IRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.
Technical Analysis
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
Active Biotech AB
―
Initiator Pharma A/S
―